← ANALYST RATINGS · TIPRANKS
Gilead Sciences (GILD): analyst forecast and price target
Price targets and ratings of
Analyst consensus
Strong Buy17 Buy4 Hold0 Sell
Ratings of 21 analysts in the last 3 months12-month forecast
$160+2.4% upside
Based on 21 price targets given in the last 3 months, the average target is $160, the highest $177, the lowest $126. The average is +2.4% from the last price of $156.
Highest target $177
Average target $160
Lowest target $126
Analyst ratings 35
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi Drug Manufacturers - GeneralxAI Grok-3 | TipRanks - xAI | $164 → $175+6.7% | Buy | +12.0% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI DeepSeek Drug Manufacturers - GeneralDeepSeek R1-0528 | TipRanks - DeepSeek | $164 → $175+6.7% | Buy | +12.0% | Upgrade | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI OpenAI Drug Manufacturers - GeneralOpenAI 4o | TipRanks - OpenAI | $163 → $173+6.1% | Buy | +10.8% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI Anthropic Drug Manufacturers - GeneralAnthropic Opus-4.1 | TipRanks - Anthropic | $158 → $168+6.3% | Hold | +7.6% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI Google Drug Manufacturers - GeneralGemini 2.5Pro | TipRanks - Google | $169 → $180+6.5% | Buy | +15.2% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI PerPlexity Drug Manufacturers - GeneralPerPlexity SonarPro | TipRanks - PerPlexity | $152 → $166+9.2% | Hold | +6.3% | Downgrade | 17.10.26on TipRanks Oct 16 23:05 | — | |
| Daina Graybosch★★★★★★★★★★#12254 · hits 39% · avg −7.8% | Leerink Partners | $130 → $129−0.8% | Hold | −17.4% | Assigned | 15.10.26on TipRanks 07:55 | +2.2%next day +0.4% | ↗ |
| AI xAi Drug Manufacturers - GeneralxAI Grok-3 | TipRanks - xAI | $168 → $164−2.4% | Buy | +5.0% | Reiterated | 15.10.26on TipRanks Oct 14 23:06 | — | |
| AI DeepSeek Drug Manufacturers - GeneralDeepSeek R1-0528 | TipRanks - DeepSeek | $168 → $164−2.4% | Buy | +5.0% | Upgrade | 15.10.26on TipRanks Oct 14 23:06 | — | |
| AI OpenAI Drug Manufacturers - GeneralOpenAI 4o | TipRanks - OpenAI | $166 → $163−1.8% | Buy | +4.4% | Reiterated | 15.10.26on TipRanks Oct 14 23:06 | — | |
| AI Anthropic Drug Manufacturers - GeneralAnthropic Opus-4.1 | TipRanks - Anthropic | $161 → $158−1.9% | Hold | +1.2% | Reiterated | 15.10.26on TipRanks Oct 14 23:06 | — | |
| AI Google Drug Manufacturers - GeneralGemini 2.5Pro | TipRanks - Google | $173 → $169−2.3% | Buy | +8.2% | Reiterated | 15.10.26on TipRanks Oct 14 23:06 | — | |
| Mohit Bansal★★★★★★★★★★#754 · hits 60% · avg +10.9% | Wells Fargo | $165 | Buy | +5.6% | Assigned | 13.10.26on TipRanks Oct 14 05:30 | −1.7%next day +4.9% | ↗ |
| AI xAi Drug Manufacturers - GeneralxAI Grok-3 | TipRanks - xAI | $163 → $168+3.1% | Buy | +7.6% | Reiterated | 13.10.26on TipRanks Oct 12 23:06 | — | |
| AI DeepSeek Drug Manufacturers - GeneralDeepSeek R1-0528 | TipRanks - DeepSeek | $163 → $168+3.1% | Buy | +7.6% | Upgrade | 13.10.26on TipRanks Oct 12 23:06 | — | |
| AI OpenAI Drug Manufacturers - GeneralOpenAI 4o | TipRanks - OpenAI | $162 → $166+2.5% | Buy | +6.3% | Reiterated | 13.10.26on TipRanks Oct 12 23:06 | — | |
| AI Anthropic Drug Manufacturers - GeneralAnthropic Opus-4.1 | TipRanks - Anthropic | $157 → $161+2.5% | Hold | +3.1% | Reiterated | 13.10.26on TipRanks Oct 12 23:06 | — | |
| AI Google Drug Manufacturers - GeneralGemini 2.5Pro | TipRanks - Google | $168 → $173+3.0% | Buy | +10.8% | Reiterated | 13.10.26on TipRanks Oct 12 23:06 | — | |
| Evan Seigerman★★★★★★★★★★#856 · hits 59% · avg +9.3% | BMO Capital | $174 | Buy | +11.4% | Reiterated | 12.10.26on TipRanks 12:55 | −0.4%next day −1.7% | ↗ |
| Geoff Meacham★★★★★★★★★★#407 · hits 60% · avg +15.3% | Citi | $165 | Buy | +5.6% | Reiterated | 12.10.26on TipRanks 07:50 | −0.4%next day −1.7% | ↗ |
| Tazeen Ahmad★★★★★★★★★★#1537 · hits 60% · avg +5.8% | Bank of America Securities | $162 → $168+3.7% | Buy | +7.6% | Reiterated | 12.10.26on TipRanks 06:50 | −0.4%next day −1.7% | ↗ |
| AI Anthropic Drug Manufacturers - GeneralAnthropic Opus-4.1 | TipRanks - Anthropic | $156 → $157+0.6% | Hold | +0.5% | Reiterated | 11.10.26on TipRanks Oct 10 23:05 | — | |
| Michael Yee★★★★★★★★★★#3077 · hits 49% · avg +3.8% | UBS | $175 | Buy | +12.0% | Reiterated | 09.10.26on TipRanks 09:15 | +2.2%next day −0.4% · 5 days +5.3% | ↗ |
| AI xAi Drug Manufacturers - GeneralxAI Grok-3 | TipRanks - xAI | $161 → $163+1.2% | Buy | +4.4% | Reiterated | 09.10.26on TipRanks Oct 8 23:06 | — | |
| AI DeepSeek Drug Manufacturers - GeneralDeepSeek R1-0528 | TipRanks - DeepSeek | $161 → $163+1.2% | Buy | +4.4% | Upgrade | 09.10.26on TipRanks Oct 8 23:06 | — | |
| AI OpenAI Drug Manufacturers - GeneralOpenAI 4o | TipRanks - OpenAI | $159 → $162+1.9% | Buy | +3.7% | Reiterated | 09.10.26on TipRanks Oct 8 23:06 | — | |
| AI Anthropic Drug Manufacturers - GeneralAnthropic Opus-4.1 | TipRanks - Anthropic | $154 → $156+1.3% | Hold | −0.1% | Reiterated | 09.10.26on TipRanks Oct 8 23:06 | — | |
| AI Google Drug Manufacturers - GeneralGemini 2.5Pro | TipRanks - Google | $166 → $168+1.2% | Buy | +7.6% | Reiterated | 09.10.26on TipRanks Oct 8 23:06 | — | |
| Brian Abrahams★★★★★★★★★★#481 · hits 57% · avg +15.1% | RBC Capital | $123 → $126+2.4% | Hold | −19.3% | Reiterated | 08.10.26on TipRanks 08:55 | +0.6%next day +2.2% · 5 days +7.3% | ↗ |
| Louise Chen★★★★★★★★★★#1899 · hits 52% · avg +5.9% | Scotiabank | $177 | Buy | +13.3% | Assigned | 08.10.26on TipRanks 08:10 | +0.6%next day +2.2% · 5 days +7.3% | ↗ |
| Gregory Renza★★★★★★★★★★#373 · hits 55% · avg +18.8% | Truist Financial | $150 → $158+5.3% | Buy | +1.2% | Reiterated | 07.10.26on TipRanks 09:05 | +2.1%next day +0.6% · 5 days +5.5% | ↗ |
| Terence Flynn★★★★★★★★★★#815 · hits 60% · avg +10.8% | Morgan Stanley | $163 | Buy | +4.4% | Reiterated | 07.10.26on TipRanks 08:15 | +2.1%next day +0.6% · 5 days +5.5% | ↗ |
| Chris Schott★★★★★★★★★★#1915 · hits 58% · avg +5.7% | J.P. Morgan | $160 → $170+6.2% | Buy | +8.8% | Reiterated | 07.10.26on TipRanks 07:31 | +2.1%next day +0.6% · 5 days +5.5% | ↗ |
| AI xAi Drug Manufacturers - GeneralxAI Grok-3 | TipRanks - xAI | $164 → $161−1.8% | Buy | +3.1% | Reiterated | 05.10.26on TipRanks Oct 4 23:06 | — | |
| AI DeepSeek Drug Manufacturers - GeneralDeepSeek R1-0528 | TipRanks - DeepSeek | $164 → $161−1.8% | Buy | +3.1% | Upgrade | 05.10.26on TipRanks Oct 4 23:06 | — | |
| AI OpenAI Drug Manufacturers - GeneralOpenAI 4o | TipRanks - OpenAI | $162 → $159−1.9% | Buy | +1.8% | Reiterated | 05.10.26on TipRanks Oct 4 23:06 | — | |
| AI Anthropic Drug Manufacturers - GeneralAnthropic Opus-4.1 | TipRanks - Anthropic | $157 → $154−1.9% | Hold | −1.4% | Reiterated | 05.10.26on TipRanks Oct 4 23:06 | — | |
| AI Google Drug Manufacturers - GeneralGemini 2.5Pro | TipRanks - Google | $169 → $166−1.8% | Buy | +6.3% | Reiterated | 05.10.26on TipRanks Oct 4 23:06 | — | |
| AI xAi Drug Manufacturers - GeneralxAI Grok-3 | TipRanks - xAI | $168 → $164−2.4% | Buy | +5.0% | Reiterated | 03.10.26on TipRanks Oct 2 23:06 | — | |
| AI DeepSeek Drug Manufacturers - GeneralDeepSeek R1-0528 | TipRanks - DeepSeek | $168 → $164−2.4% | Buy | +5.0% | Upgrade | 03.10.26on TipRanks Oct 2 23:06 | — | |
| AI OpenAI Drug Manufacturers - GeneralOpenAI 4o | TipRanks - OpenAI | $166 → $162−2.4% | Buy | +3.7% | Reiterated | 03.10.26on TipRanks Oct 2 23:06 | — | |
| AI Anthropic Drug Manufacturers - GeneralAnthropic Opus-4.1 | TipRanks - Anthropic | $161 → $157−2.5% | Hold | +0.5% | Reiterated | 03.10.26on TipRanks Oct 2 23:06 | — | |
| AI Google Drug Manufacturers - GeneralGemini 2.5Pro | TipRanks - Google | $173 → $169−2.3% | Buy | +8.2% | Reiterated | 03.10.26on TipRanks Oct 2 23:06 | — | |
| AI xAi Drug Manufacturers - GeneralxAI Grok-3 | TipRanks - xAI | $168 | Buy | +7.6% | Reiterated | 01.10.26on TipRanks Sep 30 23:06 | — | |
| AI DeepSeek Drug Manufacturers - GeneralDeepSeek R1-0528 | TipRanks - DeepSeek | $168 | Buy | +7.6% | Upgrade | 01.10.26on TipRanks Sep 30 23:06 | — | |
| AI OpenAI Drug Manufacturers - GeneralOpenAI 4o | TipRanks - OpenAI | $166 | Buy | +6.3% | Reiterated | 01.10.26on TipRanks Sep 30 23:06 | — | |
| AI Anthropic Drug Manufacturers - GeneralAnthropic Opus-4.1 | TipRanks - Anthropic | $161 | Hold | +3.1% | Reiterated | 01.10.26on TipRanks Sep 30 23:06 | — | |
| AI Google Drug Manufacturers - GeneralGemini 2.5Pro | TipRanks - Google | $173 | Buy | +10.8% | Reiterated | 01.10.26on TipRanks Sep 30 23:06 | — | |
| Michael Yee★★★★★★★★★★#3077 · hits 49% · avg +3.8% | UBS | $175 | Buy | +12.0% | Reiterated | 24.09.26on TipRanks Sep 25 06:25 | −1.0%next day +0.3% · 5 days −1.0% | ↗ |
| Morten Herholdt★★★★★★★★★★#4305 · hits 69% · avg +8.7% | HSBC | $155 → $175+12.9% | Buy | +12.0% | Reiterated | 10.09.26on TipRanks 06:30 | 0.0%next day −1.6% · 5 days +4.2% | ↗ |
| Brian Abrahams★★★★★★★★★★#481 · hits 57% · avg +15.1% | RBC Capital | $123 | Hold | −21.2% | Reiterated | 09.09.26on TipRanks Sep 10 21:45 | −0.2%next day 0.0% · 5 days +3.1% | ↗ |
| Courtney Breen★★★★★★★★★★#1339 · hits 85% · avg +18.9% | Bernstein | $160 | Buy | +2.4% | Reiterated | 07.09.26on TipRanks 12:20 | −2.3%next day −0.2% · 5 days +1.4% | ↗ |
| Salim Syed★★★★★★★★★★#7609 · hits 44% · avg +0.2% | Mizuho Securities | $170 | Buy | +8.8% | Reiterated | 31.08.26on TipRanks 10:50 | +0.8%next day +3.1% · 5 days +0.3% | ↗ |
| Gregory Renza★★★★★★★★★★#373 · hits 55% · avg +18.8% | Truist Financial | — | Buy | — | Reiterated | 28.08.26on TipRanks 08:55 | −1.9%next day +0.8% · 5 days +3.5% | ↗ |
| Louise Chen★★★★★★★★★★#1899 · hits 52% · avg +5.9% | Scotiabank | $177 | Buy | +13.3% | Reiterated | 28.08.26on TipRanks 07:36 | −1.9%next day +0.8% · 5 days +3.5% | ↗ |
| Evan Seigerman★★★★★★★★★★#856 · hits 59% · avg +9.3% | BMO Capital | $174 | Buy | +11.4% | Reiterated | 27.08.26on TipRanks Aug 28 08:35 | −0.1%next day −1.9% · 5 days +1.3% | ↗ |
| Terence Flynn★★★★★★★★★★#815 · hits 60% · avg +10.8% | Morgan Stanley | $165 | Buy | +5.6% | Reiterated | 20.08.26on TipRanks Aug 21 10:14 | −2.0%next day +1.5% · 5 days +2.7% | ↗ |
| AI PerPlexity Drug Manufacturers - GeneralPerPlexity SonarPro | TipRanks - PerPlexity | $154 → $152−1.3% | Hold | −2.7% | Downgrade | 20.08.26on TipRanks Aug 19 23:06 | — | |
| Emily Field★★★★★★★★★★#5009 · hits 45% · avg +1.9% | Barclays | $145 | Hold | −7.2% | Reiterated | 13.08.26on TipRanks Aug 14 04:35 | +1.0%next day +0.4% · 5 days +5.8% | ↗ |
| Michael Okunewitch★★★★★★★★★★#11525 · hits 36% · avg −3.3% | Maxim Group | $165 | Buy | +5.6% | Reiterated | 06.08.26on TipRanks Aug 7 18:05 | −0.5%next day +1.2% · 5 days +4.4% | ↗ |
| Chris Schott★★★★★★★★★★#1915 · hits 58% · avg +5.7% | J.P. Morgan | $160 | Buy | +2.4% | Reiterated | 06.08.26on TipRanks Aug 5 12:12 | −2.4%next day −0.5% · 5 days +2.8% | ↗ |
| Umer Raffat★★★★★★★★★★#2336 · hits 50% · avg +9.4% | Evercore ISI | — | Buy | — | Reiterated | 05.08.26on TipRanks 10:35 | −2.4%next day −0.5% · 5 days +2.8% | ↗ |
| Tazeen Ahmad★★★★★★★★★★#1537 · hits 60% · avg +5.8% | Bank of America Securities | $162 | Buy | +3.7% | Reiterated | 05.08.26on TipRanks 09:05 | −2.4%next day −0.5% · 5 days +2.8% | ↗ |
| Mohit Bansal★★★★★★★★★★#754 · hits 60% · avg +10.9% | Wells Fargo | $165 | Buy | +5.6% | Assigned | 05.08.26on TipRanks 05:11 | −2.4%next day −0.5% · 5 days +2.8% | ↗ |
| Joseph Stringer★★★★★★★★★★#293 · hits 48% · avg +24.7% | Needham | $170 | Buy | +8.8% | Reiterated | 05.08.26on TipRanks 04:46 | −2.4%next day −0.5% · 5 days +2.8% | ↗ |
| Carter Gould★★★★★★★★★★#2194 · hits 53% · avg +6.3% | Cantor Fitzgerald | $155 | Buy | −0.8% | Reiterated | 04.08.26on TipRanks Aug 5 07:55 | +1.3%next day −2.4% · 5 days +0.5% | ↗ |
| Tyler Van Buren★★★★★★★★★★#42 · hits 64% · avg +38.8% | TD Cowen | $160 | Buy | +2.4% | Assigned | 04.08.26on TipRanks Aug 5 02:55 | +1.3%next day −2.4% · 5 days +0.5% | ↗ |
| Geoff Meacham★★★★★★★★★★#407 · hits 60% · avg +15.3% | Citi | $165 | Buy | +5.6% | Reiterated | 04.08.26on TipRanks 07:45 | +1.3%next day −2.4% · 5 days +0.5% | ↗ |
| Salveen Richter★★★★★★★★★★#967 · hits 51% · avg +12.5% | Goldman Sachs | $130 | Hold | −16.8% | Reiterated | 03.08.26on TipRanks Aug 4 10:23 | −0.7%next day +1.3% · 5 days −0.6% | ↗ |
| Daina Graybosch★★★★★★★★★★#12254 · hits 39% · avg −7.8% | Leerink Partners | $146 → $127−13.0% | Hold | −18.7% | Downgrade | 20.07.26on TipRanks Jul 23 21:16 | −0.6%next day −3.0% · 5 days −1.6% | ↗ |
| Akash Tewari★★★★★★★★★★#649 · hits 57% · avg +13.5% | Jefferies | $180 | Buy | +15.2% | Reiterated | 22.05.26on TipRanks 10:25 | +2.6%next day −1.1% · 5 days −4.2% | ↗ |
| Unknown Analyst | Argus Research | $165 | Buy | +5.6% | Reiterated | 15.05.26on TipRanks May 20 08:20 | −0.7%next day +0.1% · 5 days +2.8% | ↗ |
| Brian Skorney★★★★★★★★★★#12116 · hits 37% · avg −5.6% | Robert W. Baird | $108 → $145+34.3% | Hold | −7.2% | Reiterated | 11.02.26on TipRanks 07:38 | +5.8%next day −1.0% · 5 days −1.9% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Gilead Sciences
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $159 at a price of $149 (+6.7%); now: $160 at $156 (+2.4%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 41 | 58 | 53 | 56 | 35 | 31 |
| Hold | 12 | 13 | 13 | 11 | 9 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 29.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $2.18 (from $1.99 to $2.36). Last quarter: $-6.75.
Sales
Next quarter’s sales estimate — $7.8B (from $7.7B to $7.9B). Last quarter: $7.8B.
Best top-analyst consensus in the sector · Healthcare
About Gilead Sciences
- CEO: Daniel O'Day
- Employees: 17,000
- 333 Lakeside Drive, Foster City, CA, 94404, US
- www.gilead.com
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
Data from the stock’s TipRanks forecast page, read 9 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗